Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.
Section Overview

Therapeutic Area

Metabolic

Cardiovascular

Oncology

Respiratory

Inflammation
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.
See all products

Products

Metabolic

View

Champs Opens in new tab

Empagliflozin

Linagliptin

Inflamation

View

Nintedanib

Oncology

View

Giotrif

Cardiovascular

View

Dabigatran etexilate

Telmisartan

Respiratory

View

Tiotropium + Olodaterol
Resources
Contact
Logout

Boehringer Ingelheim

All Specialties
Cardiology
Nephrology
Endocrinology
Primary Care
Prescribing Information

Banner

Heart failure treatment from then to now (Full; Day 1)

Featuring
Professor Andrew Coats | Australia

Home
List of Products HCPs
All Specialties
Past Events
Heart failure treatment from then to now (Full; Day 1)

Related content

Document ID: PC-ASK-100167

Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)

The heart failure patient through a holistic lens (Full)

Watch now Opens in new tab

Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)

The heart failure patient through a holistic lens (Summary)

Watch now Opens in new tab

Subodh Verma (Canada) | Soo Yong Lee (Korea)

SGLT2 inhibitor: Essential foundation for heart failure treatment (Summary 2)

Watch now Opens in new tab

Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)

Clinical relationship between the heart and the kidneys

Watch now Opens in new tab

Christiane Angermann (Germany) | Ricardo Carvalho (Portugal)

Why is empagliflozin now a preferred heart failure treatment, coming from a history of diabetes?

Watch now Opens in new tab

Therapeutic Area

Resources

BI logo

Privacy
Terms of use
Sitemap
Contact

This website is intended for healthcare professionals in Singapore. The contents of this website are for information purposes only and are not intended to substitute for advice, treatment or recommendations of a healthcare professional. For your health concerns and other questions about symptoms, treatment or medication, consult a healthcare professional.

Copyright © 2024 Boehringer Ingelheim Singapore Pte. Ltd.
All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement.